Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionGolden State Equity Partners
Latest Disclosed Ownership476 shares
Latest Disclosed Value $ 367,775
Golden State Equity Partners reports 34.08% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 28, 2026 - Golden State Equity Partners filed a 13F-HR form disclosing ownership of 476 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $367,775 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 355 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 34.08% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-28 2026-03-31 13F REGENERON PHARMACEUTICAL COMMON STOCK 75886F107 476 121 34.08 368 33.94 0.0084
2026-01-29 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 355 -591 -62.47 274 -48.40 0.0442
2025-10-21 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 946 71 8.11 532 15.69 0.0897
2025-07-14 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 875 -571 -39.49 459 -49.95 0.0851
2025-04-23 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,446 88 6.48 917 -5.17 0.1815
2025-01-24 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,358 1,272 1,479.07 967 974.44 0.1848
2024-10-29 2024-09-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 86 86 90 0.0476
2021-11-15 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -558 -100.00 0 -100.00
2021-08-12 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 558 558 312 0.1204
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.